INmune Bio Inc. Reports Q3 2025 Business Progress and Results
Overview of INmune Bio Inc. and Financial Performance
INmune Bio Inc. (NASDAQ: INMB), an innovative clinical-stage biotechnology company, continues to make strides in its mission to harness the innate immune system to combat various diseases. The recent announcement of its financial results for the third quarter showcases significant progress in its research and business operations, along with a commitment to improving patient outcomes.
Key Highlights from Q3 2025
During Q3 2025, INmune achieved several important milestones within its product platforms, demonstrating its ongoing dedication to developing transformative therapies. The progress made in the CORDStrom™ platform stands out as a highlight:
CORDStrom™ Platform Developments
In recent months, INmune Bio has completed the first two commercial pilot-scale manufacturing runs of CORDStrom™ at CGT Catapult. This essential step is in preparation for forthcoming regulatory filings, aiming for approval of CORDStrom™ as a treatment for recessive dystrophic epidermolysis bullosa (RDEB). The company is on track to submit a Marketing Authorization Application (MAA) by mid-2026, with a Biologics License Application (BLA) filing expected to follow shortly. The buzz surrounding CORDStrom™ reached new heights with a patient insight featured in a recent news article, further emphasizing its importance.
DN-TNF (XPro™) Highlights
The DN-TNF platform, specifically the XPro™ product, has also made headlines. A manuscript detailing findings from the Phase 2 MINDFuL trial in early Alzheimer’s Disease was submitted for peer review, showcasing the promising effects of XPro™. Results indicate that patients with higher drug exposure displayed significant cognitive benefits, suggesting an enhanced therapeutic impact attributed to adherence to the treatment. The safety profile of XPro™ remains exemplary, with no reported adverse cases of amyloid-related imaging abnormalities (ARIA), indicating its potential for use in vulnerable patient populations.
Updates on INKmune® Platform
Turning to cancer therapies, the INKmune® platform has shown its potential through the successful completion of the CARE-PC trial. Preliminary analyses revealed promising results, including evidence of natural killer (NK) cell proliferation and memory-like NK cells in treated patients. While full data analysis is ongoing, the outcomes suggest that INKmune® is on its way to contributing meaningfully to the treatment landscape for various cancers.
Financial Summary for Q3 2025
In financial terms, INmune Bio reported a net loss attributable to common stockholders of around $6.5 million for the quarter ended September 30, 2025, a notable reduction from the $12.1 million loss recorded during the same quarter last year. Research and development expenses totaled approximately $4.9 million, down from $10.1 million a year earlier, reflecting improved operational efficiencies.
Moreover, as of September 30, 2025, the company held cash and cash equivalents amounting to approximately $27.7 million, ensuring ample resources for ongoing and future projects. Overall, INmune has around 26.6 million common shares outstanding, indicative of its growing shareholder base.
Upcoming Initiatives and Events
Looking ahead, several significant events are on the horizon for INmune Bio. Key presentations are scheduled for Q4 2025, including further data on CORDStrom™ and imaging results from the MINDFuL trial. These presentations will be critical in maintaining stakeholder interests and advancing the company’s clinical agenda.
About INmune Bio Inc.
INmune Bio Inc. is a clinical-stage biotechnology firm driven by innovation in immune therapies. The company's strategic vision includes developing three prominent product platforms that address unmet medical needs: the Dominant-Negative TNF product platform (XPro™), the CORDStrom™ platform for regenerative medicine, and the INKmune® platform targeting cancer treatment.
Contact Information
For further inquiries or detailed information, interested parties can contact:
David Moss
Chief Executive Officer
(561) 710-0512
info@inmunebio.com
Daniel Carlson
Head of Investor Relations
(415) 509-4590
dcarlson@inmunebio.com
Frequently Asked Questions
What were the main financial results for Q3 2025?
INmune Bio reported a net loss of approximately $6.5 million, significantly reduced compared to the previous year.
What advancements were made in the CORDStrom™ platform?
The company completed two pilot-scale manufacturing runs and is preparing for regulatory filings to seek approval for treating RDEB.
What is the significance of XPro™ in Alzheimer’s research?
XPro™ showed promising cognitive benefits in Alzheimer's patients, indicating its potential effectiveness and safety profile.
What is INKmune® designed for?
INKmune® aims to convert resting NK cells into tumor-killing memory-like NK cells, offering novel cancer treatment options.
How can I reach out to INmune Bio Inc.?
For inquiries, you can contact David Moss or Daniel Carlson via their provided contact information.
About The Author
Contact Ryan Hughes privately here. Or send an email with ATTN: Ryan Hughes as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
